Comparison of the Breast Tumor Microenvironment

  • STATUS
    Recruiting
  • End date
    Dec 31, 2024
  • participants needed
    30
  • sponsor
    Columbia University
Updated on 2 September 2021
cancer
carcinoma
breast cancer
growth factor
epidermal growth factor receptor
HER2
EGFR
lobular carcinoma
triple negative breast cancer
erbb2
epidermal growth factor
breast carcinoma
invasive breast cancer
breast-conserving surgery
mammogram
core needle biopsy

Summary

The goal of the project is to identify a molecular signature of tumor stroma from "normal" adjacent breast tissue obtained prospectively at the time of breast conserving surgery before and after receiving intraoperative radiation therapy (IORT) in subjects that have luminal A and triple negative breast cancer. IORT is considered as being standard of care.

Description

There is evidence that the normal tissue around a tumor plays a role in determining how the tumor behaves, including how it responds to treatments and how likely it is to recur.

Details
Condition Breast Cancer, Metastatic Triple-Negative Breast Cancer, Triple Negative Breast Cancer, Chronic Diarrhea, Skin Wounds, Chronic Shoulder Pain, Injection Port, Peripheral Arterial Occlusive Disease, Brain Function, Primary Immunodeficiency, Near-Sighted Corrective Surgery, Breast Cancer - HER2 Positive, Diet and Nutrition, Razor Bumps (Pseudofolliculitis Barbae), Vaginal Atrophy, Anal Dysplasia, Hormone Receptor Positive Malignant Neoplasm of Breast, Recurrent Respiratory Papillomatosis, Pediatric Health, Adverse Effects, Drugs
Treatment Blood sample collection, Breast tissue collection
Clinical Study IdentifierNCT03165487
SponsorColumbia University
Last Modified on2 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Female, age greater than or equal to 40
Core biopsy proven invasive breast carcinoma or DCIS, all subtypes excluding invasive lobular carcinoma due to increased risk for multifocal disease
Human epidermal growth factor receptor 2 (HER2) negative regardless of hormone receptor status
Clinically less than or equal to 3cm unifocal lesion
Clinically node negative
Must have diagnostic mammogram performed within last 6 months
Eastern Cooperative Oncology Group Performance Status (ECOG PS) less than or equal to 1
Appropriate renal, liver, and hematologic lab values
Ability to give informed consent

Exclusion Criteria

Multifocal disease
Clinically N1 disease at diagnosis
Invasive lobular carcinoma
Metastatic disease
Patients for whom RT would be contraindicated (e.g., connective tissue disorder or prior ipsilateral breast radiation)
Patients with known BRCA1/2 mutations
Pregnant or nursing
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note